国际口腔医学杂志

国际口腔医学杂志 ›› 2018, Vol. 45 ›› Issue (5): 584-589.doi: 10.7518/gjkq.2018.05.015

• 综述 • 上一篇    下一篇

慢性黏膜皮肤念珠菌病的治疗进展

冯璐,孟文霞()   

  1. 南方医科大学口腔医院黏膜病科 广州 510280
  • 收稿日期:2018-03-17 修回日期:2018-06-02 出版日期:2018-09-01 发布日期:2018-09-20
  • 通讯作者: 孟文霞
  • 作者简介:冯璐,硕士,Email：fenglu200306@126.com
  • 基金资助:
    国家自然科学基金(81500850)

Therapeutic progress of chronic mucocutaneous candidiasis disease

Lu Feng,Wenxia. Meng()   

  1. Dept. of Oral Medicine, Stomatological Hospital, Southern Medical University, Guangzhou 510280, China
  • Received:2018-03-17 Revised:2018-06-02 Online:2018-09-01 Published:2018-09-20
  • Contact: Wenxia. Meng
  • Supported by:
    This study was supported by National Natural Science Foundation of China(81500850)

RichHTML

11

PDF (PC)

375

摘要：

慢性黏膜皮肤念珠菌病（CMCD）是一种特殊类型的念珠菌感染,被认为是免疫缺陷相关性疾病,其发病机制复杂,治疗较为棘手。常规抗真菌药物已不能满足临床上对该病的治疗需求。随着研究发展,一些新型分子制剂对CMCD的治疗表现出巨大潜力。本文回顾了目前国内外对CMCD的治疗现状及未来的发展方向,以期为临床医生提供多重选择。

关键词: 慢性黏膜皮肤念珠菌病, 治疗, 分子制剂

Abstract:

Chronic mucocutaneous candidiasis disease (CMCD) is a special type of Candida albicans infection, which is identified associated with immunodeficiency. The pathogenesis is complex and the treatment is more difficult. Conventional antifungal drugs have failed to meet the clinical demands. With the development of various treatment studies expanding, new molecular agents have shown great potential for the treatment of CMCD. This review summarizes the current status of treatment and future development of CMCD, in order to provide more information for clinicians.

Key words: chronic mucocutaneous candidiasis disease, treatment, molecular agents

中图分类号: 

  • R781.5 +4
[1] Papazian CE, Koch R , Monilial granuloma with hypo- thyroidism: report of a case treated with amphotericin B[J]. N Engl J Med, 1960,262:16-18.
doi: 10.1056/NEJM196001072620104
[2] Puel A, Picard C, Cypowyj S , et al. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines[J]. Curr Opin Immunol, 2010,22(4):467-474.
doi: 10.1016/j.coi.2010.06.009
[3] Smeekens SP , Plantinga TS, van de Veerdonk FL, et al. STAT1 hyperphosphorylation and defective IL12R/ IL23R signaling underlie defective immunity in auto- somal dominant chronic mucocutaneous candidiasis[J]. PLoS One, 2011,6(12):e29248.
doi: 10.1371/journal.pone.0029248
[4] Liu L, Okada S, Kong XF , et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis[J]. J Exp Med, 2011,208(8):1635-1648.
doi: 10.1084/jem.20110958
[5] Al Rushood M , McCusker C, Mazer B, et al. Autoso-mal dominant cases of chronic mucocutaneous can-didiasis segregates with mutations of signal transdu-cer and activator of transcription 1, but not of Toll-like receptor 3[J]. J Pediatr, 2013,163(1):277-279.
doi: 10.1016/j.jpeds.2013.02.040
[6] Martinez-Martinez L, Martinez-Saavedra MT , Fue-ntes-Prior P, et al. A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis[J]. Mol Immunol, 2015,68(2 Pt C):597-605.
doi: 10.1016/j.molimm.2015.09.014
[7] Soltész B, Tóth B, Shabashova N , et al. New and re-current gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe[J]. J Med Genet, 2013,50(9):567-578.
doi: 10.1136/jmedgenet-2013-101570
[8] Dotta L, Scomodon O, Padoan R , et al. Clinical he-terogeneity of dominant chronic mucocutaneous can-didiasis disease: presenting as treatment-resistant candidiasis and chronic lung disease[J]. Clin Immunol, 2016,164:1-9.
doi: 10.1016/j.clim.2015.12.010
[9] Yamazaki Y, Yamada M, Kawai T , et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody[J]. J Immunol, 2014,193(10):4880-4887.
doi: 10.4049/jimmunol.1401467
[10] Lorenzini T, Dotta L, Giacomelli M , et al. STAT mu- tations as program switchers: turning primary immu-nodeficiencies into autoimmune diseases[J]. J Leukoc Biol, 2017,101(1):29-38.
doi: 10.1189/jlb.5RI0516-237RR pmid: 27803128
[11] Depner M, Fuchs S, Raabe J , et al. The extended clinical phenotype of 26 patients with chronic mucocu- taneous candidiasis due to gain-of-function mutations in STAT1[J]. J Clin Immunol, 2016,36(1):73-84.
doi: 10.1007/s10875-015-0214-9
[12] Puel A, Cypowyj S, Bustamante J , et al. Chronic mu-cocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity[J]. Science, 2011,332(6025):65-68.
doi: 10.1126/science.1200439 pmid: 21350122
[13] McDonald DR . Th17 deficiency in human disease[J]. J Allergy Clin Immunol, 2012,129(6):1429-1437.
doi: 10.1016/j.jaci.2012.03.034 pmid: 3388506
[14] Petersen EA, Alling DW, Kirkpatrick CH , Treatment of chronic mucocutaneous candidiasis with ketoco-nazole: a controlled clinical trial[J]. Ann Intern Med, 1980,93(6):791-795.
doi: 10.7326/0003-4819-93-6-791
[15] Mobacken H, Moberg S , Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis. A prospective 3-year trial[J]. Dermatologica, 1986,173(5):229-236.
doi: 10.1159/000249259 pmid: 3100354
[16] Ahonen P, Myllärniemi S, Kahanpää A , et al. Keto-conazole is effective against the chronic mucocuta-neous candidosis of autoimmune polyendocrinopa-thy-candidosis-ectodermal dystrophy (APECED)[J]. Acta Med Scand, 1986,220(4):333-339.
[17] Kim JH, Choi WG, Moon JY , et al. Metabolomics-assisted metabolite profiling of itraconazole in human liver preparations[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2018,1083:68-74.
doi: 10.1016/j.jchromb.2018.02.041 pmid: 29524695
[18] Jachiet M, Lanternier F, Rybojad M , et al. Posacona-zole treatment of extensive skin and nail dermato-phytosis due to autosomal recessive deficiency of CARD9[J]. JAMA Dermatol, 2015,151(2):192-194.
doi: 10.1001/jamadermatol.2014.2154
[19] 曹江, 江学维, 章成 , 等. 泊沙康唑抗侵袭性真菌感染文献计量分析[J]. 中华医院感染学杂志, 2017,27(24):5537-5540.
Cao J, Jiang XW, Zhang C , et al. Quantitative analysis of posaconazole in the treatment of invasive fungal infection[J]. Chin J Nosocomiol, 2017,27(24):5537-5540.
[20] Alves de Medeiros AK, Lodewick E, Bogaert DJ , et al. Chronic and invasive fungal infections in a family with CARD9 deficiency[J]. J Clin Immunol, 2016,36(3):204-209.
doi: 10.1007/s10875-016-0255-8 pmid: 27116191
[21] Revankar SG, Nailor MD, Sobel JD , Use of terbina-fine in rare and refractory mycoses[J]. Future Micro-biol, 2008,3(1):9-17.
doi: 10.2217/17460913.3.1.9
[22] Hu Y, Hu Y, Lu Y , et al. A case report of penile infec-tion caused by fluconazole- and terbinafine-resistant Candida albicans[J]. Mycopathologia, 2017,182(3/4):397-402.
doi: 10.1007/s11046-016-0070-z
[23] Nielsen J, Kofod-Olsen E, Spaun E , et al. A STAT1-gain-of-function mutation causing Th17 deficiency with chronic mucocutaneous candidiasis, psoriasiform hyperkeratosis and dermatophytosis[J]. BMJ Case Rep, 2015, 2015: bcr2015211372.
[24] Martinez-Suarez JV, Rodriguez-Tudela JL , In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates[J]. Antimicrob Agents Chemother, 1996,40(5):1277-1279.
[25] Jayasinghe M, Schmidt S, Walker B , et al. Success-ful treatment of azoleresistant chronic mucocu-taneous candidosis with caspofungin[J]. Acta Derm Venereol, 2006,86(6):563-564.
doi: 10.2340/00015555-0165 pmid: 17106615
[26] Caínzos-Romero T, Sánchez-Trigo S, Marfil-Verchili S , et al. Treatment of chronic mucocutaneous candidia- sis, an unsolved issue. Case report and literature re-view[J]. J Clin Cell Immunol, 2017,8:501.
[27] Kirkpatrick CH , Chronic mucocutaneous candidiasis[J]. J Am Acad Dermatol, 1994,31(3 Pt 2):S14-S17.
doi: 10.1016/S0190-9622(08)81260-1
[28] Higgins E, Al Shehri T , McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal trans-ducer and activator of transcription 1 (STAT1) mutation[J]. J Allergy Clin Immunol, 2015,135(2):551-553.
doi: 10.1016/j.jaci.2014.12.1867
[29] Weinacht KG, Charbonnier LM, Alroqi F , et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 ( STAT1) gain-of-function mutation[J]. J Allergy Clin Immunol, 2017, 139(5): 1629- 1640. e2.
doi: 10.1016/j.jaci.2016.11.022
[30] Zimmerman O, Rösler B, Zerbe CS , et al. Risks of ruxolitinib in STAT1 gain-of-function-associated se- vere fungal disease[J]. Open Forum Infect Dis, 2017, 4(4): ofx202.
doi: 10.1093/ofid/ofx202 pmid: 29226168
[31] van de Veerdonk FL, Netea MG . Treatment options for chronic mucocutaneous candidiasis[J]. J Infect, 2016,72(Suppl):S56-S60.
doi: 10.1016/j.jinf.2016.04.023 pmid: 27161991
[32] Wildbaum G, Shahar E, Katz R , et al. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restora-tion of IL-17 secretion[J]. J Allergy Clin Immunol, 2013,132(3):761-764.
doi: 10.1016/j.jaci.2013.04.018
[33] Kullberg BJ, Oude Lashof AM, Netea MG , Design of efficacy trials of cytokines in combination with antifungal drugs[J]. Clin Infect Dis, 2004,39(Suppl 4):S218-S223.
doi: 10.1086/421960 pmid: 15546121
[34] van de Veerdonk FL, Koenen HJ, van der Velden WJ , et al. Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis[J]. Immunol Lett, 2015,167(1):54-56.
doi: 10.1016/j.imlet.2015.05.008 pmid: 25999307
[35] 李璟, 梁菁, 徐婷 , 等. IL-6 -572基因多态性与侵袭性牙周炎易感性的相关性研究[J]. 口腔疾病防治, 2017,25(11):718-722.
Li J, Liang J, Xu T , et al. Relationship between inter-leukin-6 -572 gene polymorphism and aggressive periodontitis in Chinese[J]. J Prevent Treatment Sto-matol Dis, 2017,25(11):718-722.
[36] Zheng J, van de Veerdonk FL, Crossland KL , et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous can-didiasis (CMC)[J]. Eur J Immunol, 2015,45(10):2834-2846.
doi: 10.1002/eji.201445344
[37] Abaza YM, Kadia TM, Jabbour EJ , et al. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies[J]. Cancer, 2017,123(24):4851-4859.
doi: 10.1002/cncr.v123.24
[38] Batlevi CL, Crump M, Andreadis C , et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma[J]. Br J Haematol, 2017,178(3):434-441.
doi: 10.1111/bjh.2017.178.issue-3
[39] Hoh MC, Lin HP, Chan LL , et al. Successful alloge-neic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome[J]. Bone Marrow Transplant, 1996,18(4):797-800.
[40] Aldave JC, Cachay E, Núñez L , et al. A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation[J]. J Clin Immunol, 2013,33(8):1273-1275.
doi: 10.1007/s10875-013-9947-5
[41] Dhalla F, Fox H, Davenport EE , et al. Chronic muco-cutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility[J]. Clin Exp Immunol, 2016,184(2):216-227.
doi: 10.1111/cei.2016.184.issue-2
[42] Koo S, Kejariwal D, Al-Shehri T , et al. Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation[J]. United European Gastroenterol J, 2017,5(5):625-631.
doi: 10.1177/2050640616684404
[43] Sampaio EP, Hsu AP, Pechacek J , et al. Signal trans-ducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioido-mycosis and histoplasmosis[J]. J Allergy Clin Immunol, 2013,131(6):1624-1634
doi: 10.1016/j.jaci.2013.01.052
[44] Tanimura M, Dohi K, Hirayama M , et al. Recurrent inflammatory aortic aneurysms in chronic mucocuta-neous candidiasis with a gain-of-function STAT1 mu- tation[J]. Int J Cardiol, 2015,196:88-90.
doi: 10.1016/j.ijcard.2015.05.183
[1] 刘世一, 陈中, 张素欣. 程序性死亡受体/配体免疫治疗策略在人乳头瘤病毒阳性头颈部鳞状细胞癌中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 21-27.
[2] 和子慕, 李风兰. 数字化口腔定位支架在头颈部肿瘤放射治疗中的应用现状[J]. 国际口腔医学杂志, 2024, 51(1): 28-35.
[3] 傅豫, 何薇, 黄兰. 铁死亡在口腔疾病中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 36-44.
[4] 韩冲,何东宁,余飞燕,吴东潮. 口腔种植术后疼痛机制及治疗的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 99-106.
[5] 胡佳,王秀清,卢国英,黄晓晶. 再生性牙髓治疗在成人根尖发育不全恒牙应用的研究进展[J]. 国际口腔医学杂志, 2023, 50(6): 686-695.
[6] 陆磊,王鑫,康泽标,谢富强. 计算机辅助导航手术在复杂颌面部骨折中的应用新进展[J]. 国际口腔医学杂志, 2023, 50(6): 696-703.
[7] 杨冬叶,朱萍,吴淑仪. 舌位的影响因素及临床意义[J]. 国际口腔医学杂志, 2023, 50(6): 723-728.
[8] 戢晓,张岚,黄定明. 牙源性与非牙源性上颌窦炎鉴别诊断及其治疗方案的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 566-572.
[9] 赵苑汐,苏勤. 根管再治疗中根管充填物去除辅助技术的应用与发展[J]. 国际口腔医学杂志, 2023, 50(5): 581-586.
[10] 宋文鹏,龚蓓文,李聃,曾剑玉,仇玲玲. 机械疗法在正畸治疗中应用的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 603-612.
[11] 刘婷,武秀萍. 唐氏综合征的口腔-颅颌面表征及治疗进展[J]. 国际口腔医学杂志, 2023, 50(5): 618-622.
[12] 吴思佳,舒畅,王洋,王媛,邓淑丽,王慧明. 根管内感染控制对年轻恒牙牙髓再生治疗的影响及研究进展[J]. 国际口腔医学杂志, 2023, 50(4): 388-394.
[13] 高宇天,苏勤. 酸性氧化电位水在根管治疗中的研究与应用[J]. 国际口腔医学杂志, 2023, 50(4): 401-406.
[14] 范琳,孙江. 微针在口腔医学中的应用[J]. 国际口腔医学杂志, 2023, 50(4): 472-478.
[15] 陈卓,石冰,李精韬. 唇腭裂患者外鼻生长特征的研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 279-286.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 王昆润. 二甲亚砜和双氯芬酸并用治疗根尖周炎[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 汤庆奋,王学侠. 17β-雌二醇对人类阴道和口腔颊粘膜的渗透性[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 潘劲松. 颈总动脉指压和颈内动脉球囊阻断试验在大脑血液动力学中的不同影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[4] 王昆润. 后牙冠根斜形牙折的治疗[J]. 国际口腔医学杂志, 1999, 26(05): .
[5] 杨锦波. 嵌合体防龋疫苗的研究进展[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 王昆润. 下颔骨成形术用网状钛板固定植骨块[J]. 国际口腔医学杂志, 1999, 26(04): .
[7] 汪月月,郭莉莉. 口腔机能与老化—痴呆危险因素流行病学研究[J]. 国际口腔医学杂志, 1999, 26(04): .
[8] 丁刚. 应用硬组织代用品种植体行丰颏术[J]. 国际口腔医学杂志, 1999, 26(04): .
[9] 田磊. 局部应用脂多糖后结合上皮反应性增生的变化[J]. 国际口腔医学杂志, 1999, 26(04): .
[10] 戴青. 口腔念珠菌病的新分类[J]. 国际口腔医学杂志, 1999, 26(04): .